

# Medical Office Update

August 2026

## In this issue

- ModaHealth.com website upgrade
- Credentialing update
- Provider workshop registration
- Cervical cancer screening
- Denosumab coverage updates
- Reimbursement policy manual June-July
- Medical necessity criteria summary May-June

## Join our email list

Join our email list to receive these bi-monthly newsletters, as well as occasional electronic communications.

[Sign up now](#)

## A new ModaHealth.com is here!

We're excited to announce the launch of the updated [ModaHealth.com](#) site, designed to better support you and your patients. This enhanced website offers a simpler, more intuitive experience and makes it easier to access the information, tools and resources you use most.

This upgrade is a significant step forward in our digital experience. While key tools and resources remain in place, you'll notice a meaningful improvement in how the site looks, feels and performs. The new experience is designed to make it faster and easier for you and your team to find information you need quickly and seamlessly.

## What's new?

The new design is built to support your needs and includes:

- Simpler navigation across desktops, tablets and mobile devices
- Modernized technology platform for a better user experience

- English and Spanish language options
- Accessibility features designed to support all users

Bookmarks for most key pages redirect to the new website, but we encourage you to bookmark the new pages.

### **What's staying the same?**

You'll continue to have access to the resources you use most, such as:

- Find Care provider directory
- Tools and resources
- Policies and manuals

Plus, your login access to [Benefit Tracker](#) and [Provider Reports](#) will remain unchanged.

### **Designed for a better experience**

We hope this enhanced digital experience makes it easier for you and your team to find the information, tools and resources you need to care for your patients and the members we serve together. Our teams are closely monitoring the transition to the new site and will quickly address any issues that may arise.

We thank you for your partnership and support in helping our members to better overall health and wellness.

---

## Credentialing is now easier

If you practice in Idaho or Alaska, you'll be able to submit your credentialing application through our new eApply portal starting Aug. 20, 2026. The portal is simple to use and lets you complete and submit your application online.

If you practice in Oregon or Texas, the eApply portal isn't available yet. We'll let you know when it becomes available.

### **Faster process, same preferred pathway**

No matter where you practice, CAQH remains our preferred way to receive credentialing applications. Keeping your CAQH profile complete and up to date helps us process your application as quickly as possible.

We've also upgraded our credentialing software to help speed up application reviews and reduce delays.

Thank you for partnering with us to care for our members. If you have questions, our Credentialing team is here to help at [credentialing@modahealth.com](mailto:credentialing@modahealth.com).

---

## Learn what's new for 2026. Sign up today!

Moda Health's Provider Relations team invites you to join our virtual provider workshops, which begin Oct. 16, 2026. These interactive sessions are a great way to stay informed, ask questions and learn about tools and resources to help you and your team work more efficiently.

**Our fall workshops will cover several important topics, including:**

- Network update/changes
- Policy updates
- Claim billing and appeals
- Quality and value-based care programs

[Sign up today](#) for the workshop that best aligns with your geographic region! These workshops will last about an hour.

We look forward to sharing our 2026 updates and providing a glimpse of what's new for 2027!

---

## Help more patients get screened for cervical cancer

Routine cervical cancer screening can find changes before they become cancer or detect cervical cancer early, when treatment is most effective. The Cervical Cancer Screening (CCS-E) HEDIS measure looks at whether individuals ages 21–64 receive appropriate screening through cervical cytology (pap smear), high-risk HPV testing or HPV/pap co-testing based on their age.

As of Measurement Year 2025, CCS-E is reported using the Electronic Clinical Data Systems (ECDS) method, which allows health plans to capture screening information from sources such as electronic health records, laboratory systems, health information exchanges and clinical registries. This creates a more complete picture of the care your patients receive.

### Expand access through self-collection

HPV self-collection test methods are emerging as an important tool to increase access to cervical cancer screening by offering eligible patients a more convenient and comfortable option. By reducing barriers to screening and supporting earlier detection of cervical cancer, self-collection can help improve screening rates, close care gaps and ultimately save lives. When billed appropriately, HPV self-collection testing counts toward the CCS-E HEDIS measure.

To learn more about patient eligibility, coding considerations and self-collection methods that can be used for cervical cancer screenings, check out the American Cancer Society's [Guide for Self-Collection](#) and [Self-Collection Clinician Communication Guide](#).

| Code system            | HEDIS accepted codes for cervical cancer screening (CCS-E)                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CPT                    | 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88164, 88165, 88166, 88167, 88174, 88175, 87624, 87625, 87626, 0502U                                                                                                                                                                                                                                                                                                         |
| HCPCS                  | G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, G0476                                                                                                                                                                                                                                                                                                                                                          |
| LOINC                  | 104866-9, 10524-7, 18500-9, 19762-4, 19765-7, 19766-5, 19774-9, 33717-0, 47527-7, 47528-5, 104132-6, 104170-6, 104752-1, 104766-1, 104783-6, 106508-5, 106509-3, 21440-3, 30167-1, 38372-9, 59263-4, 59264-2, 59420-0, 69002-4, 71431-1, 75694-0, 77379-6, 77399-4, 77400-0, 82354-2, 82456-5, 82675-0, 95539-3                                                                                                                      |
| SNOMED CT U.S. edition | 168406009, 68407000, 168408005, 168410007, 168414003, 168415002, 168416001, 168424006, 250538001, 269957009, 269958004, 269959007, 269960002, 269961003, 269963000, 275805003, 281101005, 309081009, 310841002, 310842009, 416030007, 416032004, 416033009, 439074000, 439776006, 439888000, 441087007, 441088002, 441094005, 441219009, 441667007, 700399008, 700400001, 1155766001, 62051000119105, 62061000119107, 98791000119102 |

|             |                                                            |
|-------------|------------------------------------------------------------|
| Code system | HEDIS accepted codes for cervical cancer screening (CCS-E) |
|-------------|------------------------------------------------------------|

## Denosumab coverage updates

As part of our commitment to provide members with high-quality, affordable care, Moda Health is updating our medical pharmacy coverage for **denosumab** products used to treat osteoporosis, bone loss and oncology/supportive oncology conditions.

Starting Oct. 1, 2026, Moda members starting or renewing denosumab therapy will receive the preferred product based on their condition.

Osteoporosis/bone loss (Prolia biosimilars):

- Bildyos [Q5162]
- Enoby [Q5167]

Oncology/supportive oncology (Xgeva biosimilars):

- Bilprevda [Q5162]
- Xtrenbo [Q5167]

If there's clinical documentation that the preferred denosumab products are ineffective, not tolerated or contraindicated, a non-preferred denosumab product may be covered with prior authorization from Prime Therapeutics Management or Moda Health.

Please note, prior authorization will continue to be required for all denosumab products. Site of Care (SOC) program requirements will also continue to apply when applicable. Please see our [medical necessity criteria page](#) for details.

## Additional information

Looking for additional information about this month's topics? Click the button below for our new comprehensive document. This month it will contain:

- [Reimbursement policy manual updates](#)
- [Medical necessity criteria](#)

## Moda Health Medical Customer Service

For claims review, adjustment requests and/or billing policies, please call the number shown on the back of the patient's Moda ID card.



© 2025 Moda Partners, Inc. All Rights Reserved.  
Moda Health Plan, Inc. | 601 SW Second Avenue, Portland, OR 97204

[Privacy and Transparency Center](#) | [Manage Preferences](#)

[View this email in a browser.](#)